S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:GNLX

Genelux (GNLX) Stock Forecast, Price & News

$26.88
-0.72 (-2.61%)
(As of 09/22/2023 ET)
Compare
Today's Range
$26.01
$28.12
50-Day Range
$20.27
$29.98
52-Week Range
$5.35
$40.98
Volume
109,021 shs
Average Volume
394,489 shs
Market Capitalization
$663.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Genelux MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.0% Downside
$25.00 Price Target
Short Interest
Healthy
0.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.42mentions of Genelux in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$4.45 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.26 out of 5 stars

Medical Sector

927th out of 968 stocks

Pharmaceutical Preparations Industry

425th out of 439 stocks


GNLX stock logo

About Genelux (NASDAQ:GNLX) Stock

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

GNLX Price History

GNLX Stock News Headlines

Genelux (NASDAQ:GNLX) Trading Down 6% After Insider Selling
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Genelux Director Trades Company's Stock
Genelux Co. (NASDAQ:GNLX) VP Sells $227,656.00 in Stock
Genelux (NASDAQ:GNLX) Shares Gap Down Following Insider Selling
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Genelux Co. (NASDAQ:GNLX) VP Sells $629,972.00 in Stock
Genelux (NASDAQ:GNLX) Stock Price Down 3.3% Following Insider Selling
Genelux 10% Owner Sold $1.17M In Company Stock
Genelux (NASDAQ:GNLX) Coverage Initiated by Analysts at Maxim Group
Genelux 10% Owner Trades $878K In Company Stock
Genelux Appoints Lourie Zak As New CFO
Genelux gets new finance chief
See More Headlines
Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

GNLX Company Calendar

Last Earnings
8/14/2023
Today
9/22/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNLX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
-7.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.07 million
Book Value
($1.51) per share

Miscellaneous

Free Float
21,784,000
Market Cap
$663.13 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thomas Zindrick J.D. (Age 64)
    Chairman, CEO & Pres
    Comp: $500k
  • Mr. Sean Ryder J.D. (Age 54)
    Gen. Counsel & Corp. Sec.
    Comp: $380k
  • Ms. Lourie S. Zak (Age 60)
    CFO & Principal Accounting Officer
  • Dr. Joseph Cappello Ph.D. (Age 66)
    Chief Technical Officer
  • Dr. Yong Yu Ph.D. (Age 52)
    Sr. VP of Clinical Devel.
  • Prof. Paul Scigalla M.D. (Age 77)
    Ph.D., Chief Medical Officer
  • Mr. Ralph Smalling B.Sc. (Age 67)
    Head of Regulatory Affairs
  • Ms. Caroline Jewett (Age 59)
    Head of Quality













GNLX Stock - Frequently Asked Questions

Should I buy or sell Genelux stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNLX shares.
View GNLX analyst ratings
or view top-rated stocks.

What is Genelux's stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month target prices for Genelux's shares. Their GNLX share price forecasts range from $10.00 to $40.00. On average, they expect the company's share price to reach $25.00 in the next twelve months. This suggests that the stock has a possible downside of 7.0%.
View analysts price targets for GNLX
or view top-rated stocks among Wall Street analysts.

How have GNLX shares performed in 2023?

Genelux's stock was trading at $6.01 on January 1st, 2023. Since then, GNLX stock has increased by 347.3% and is now trading at $26.88.
View the best growth stocks for 2023 here
.

Are investors shorting Genelux?

Genelux saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 166,900 shares, an increase of 8.6% from the August 15th total of 153,700 shares. Based on an average daily trading volume, of 96,300 shares, the short-interest ratio is currently 1.7 days. Approximately 0.9% of the shares of the company are short sold.
View Genelux's Short Interest
.

When is Genelux's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our GNLX earnings forecast
.

How were Genelux's earnings last quarter?

Genelux Co. (NASDAQ:GNLX) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09.

When did Genelux IPO?

(GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

What is Genelux's stock symbol?

Genelux trades on the NASDAQ under the ticker symbol "GNLX."

When did the company's lock-up period expire?

Genelux's lock-up period expired on Tuesday, July 25th. Genelux had issued 2,500,000 shares in its initial public offering on January 26th. The total size of the offering was $15,000,000 based on an initial share price of $6.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Genelux's major shareholders?

Genelux's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.55%), Geode Capital Management LLC (0.25%), State Street Corp (0.19%), Northern Trust Corp (0.13%), Hohimer Wealth Management LLC (0.09%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu.
View institutional ownership trends
.

How do I buy shares of Genelux?

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genelux's stock price today?

One share of GNLX stock can currently be purchased for approximately $26.88.

How much money does Genelux make?

Genelux (NASDAQ:GNLX) has a market capitalization of $663.13 million and generates $11.07 million in revenue each year.

How can I contact Genelux?

Genelux's mailing address is 2625 Townsgate Road Suite 230, Westlake Village CA, 91361. The official website for the company is www.genelux.com. The company can be reached via phone at 805-267-9889 or via email at genelux@allelecomms.com.

This page (NASDAQ:GNLX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -